Low in vitro activity of sertaconazole against clinical isolates of dermatophyte

Background and Purpose: Dermatophytes are a group of fungi specialized in invading humans and other vertebrate keratinized tissues. These fungi cause a variety of skin, nail, and hair disorders, called dermatophytosis (tinea). In some cases, drug resistance to antifungals necessitates special treatment. Among the antifungal agents, sertaconazole (i.e., a third-generation imidazole) has a broad-spectrum against dermatophyte species. Regarding this, the present study was conducted to investigate the antifungal susceptibility of dermatophytes obtained from patients with dermatophytosis in Mashhad located in northeastern Iran. Materials and Methods: A total of 75 clinical dermatophyte isolates, including Trichophyton mentagrophytes (n=21), T. interdigital (n=18), T. tonsurans (n=16), Epidermophyton floccosum (n=11), Microsporum canis (n=5), Nannizzia fulvum (n=2), T. benhamiae (n=1), and T. verrucosum (n=1), were evaluated against five antifungal agents of sertaconazole, itraconazole, clotrimazole, terbinafine, and griseofulvin based on the CLSI M38-A2 guideline. Results: According to the results, the minimum inhibitory concentration (MIC) ranges of sertaconazole, terbinafine, griseofulvin, itraconazole, and clotrimazole were estimated at 0.125-16, 0.002-1, 0.5-4, 0.031-4, and 0.016-4 µg/ml, respectively, for dermatophyte species. In addition, the geometric mean (GM) values of the MIC of sertaconazole, terbinafine, griseofulvin, itraconazole, and clotrimazole were obtained as 3.39, 1, 1.44, 1.52, and 1.93, respectively. Conclusion: Among the tested antifungals, terbinafine and griseofulvin were the most effective agents against dermatophyte isolates. However, sertaconazole, a third-generation imidazole, did not show any significant effect. Furthermore, M. canis and E. floccosum showed the best response to the antifungal agents.

[1]  H. Badali,et al.  In vitro activities of 15 antifungal drugs against a large collection of clinical isolates of Microsporum canis , 2019, Mycoses.

[2]  S. Dolatabadi,et al.  Molecular Identification, Genotypic Diversity, Antifungal Susceptibility, and Clinical Outcomes of Infections Caused by Clinically Underrated Yeasts, Candida orthopsilosis, and Candida metapsilosis: An Iranian Multicenter Study (2014–2019) , 2019, Front. Cell. Infect. Microbiol..

[3]  I. Khorsand,et al.  Epidemiology of dermatophytosis in northeastern Iran; A subtropical region , 2019, Current medical mycology.

[4]  A. Nasiri,et al.  Specific Identification and Antifungal Susceptibility Pattern of Clinically Important Dermatophyte Species Isolated from Patients with Dermatophytosis in Tehran, Iran , 2018, Archives of Clinical Infectious Diseases.

[5]  M. Göker,et al.  Toward a Novel Multilocus Phylogenetic Taxonomy for the Dermatophytes , 2016, Mycopathologia.

[6]  H. Badali,et al.  In vitro activity of new azoles luliconazole and lanoconazole compared with ten other antifungal drugs against clinical dermatophyte isolates. , 2016, Medical mycology.

[7]  M. Afshari,et al.  Antifungal susceptibility and virulence factors of clinically isolated dermatophytes in Tehran, Iran , 2016, Iranian journal of microbiology.

[8]  M. Ghannoum.  Azole Resistance in Dermatophytes: Prevalence and Mechanism of Action. , 2015, Journal of the American Podiatric Medical Association.

[9]  H. Badali,et al.  Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran , 2015, Mycopathologia.

[10]  H. Badali,et al.  In vitro susceptibility patterns of clinically important Trichophyton and Epidermophyton species against nine antifungal drugs , 2015, Mycoses.

[11]  S. Somashekar,et al.  Comparison of topical anti- fungal agents sertaconazole and clotrimazole in the treatment of tinea corporis-an observational study. , 2014, Journal of clinical and diagnostic research : JCDR.

[12]  K. Ferreira-Paim,et al.  Identification and antifungal susceptibility of fungi isolated from dermatomycoses , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  A. Fothergill,et al.  Luliconazole Demonstrates Potent In Vitro Activity against Dermatophytes Recovered from Patients with Onychomycosis , 2014, Antimicrobial Agents and Chemotherapy.

[14]  Y. Bulut,et al.  In vitro activities of antifungal drugs against dermatophytes isolated in Tokat, Turkey , 2013, International journal of dermatology.

[15]  S. Hashemi,et al.  In-vitro Activity of 10 Antifungal Agents against 320 Dermatophyte Strains Using Microdilution Method in Tehran , 2013, Iranian journal of pharmaceutical research : IJPR.

[16]  N. Jauregizar,et al.  Sertaconazole: an antifungal agent for the topical treatment of superficial candidiasis , 2013, Expert review of anti-infective therapy.

[17]  Aditya K. Gupta,et al.  In vitro pharmacodynamic characteristics of griseofulvin against dermatophyte isolates of Trichophyton tonsurans from tinea capitis patients. , 2009, Medical mycology.

[18]  K. Zomorodian,et al.  In vitro activity of six antifungal drugs against clinically important dermatophytes , 2009 .

[19]  J. Croxtall,et al.  Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. , 2009, Drugs.

[20]  N. Martinez-Rossi,et al.  In vitro antifungal drug susceptibilities of dermatophytes microconidia and arthroconidia. , 2008, The Journal of antimicrobial chemotherapy.

[21]  M. Ghannoum,et al.  Susceptibility of dermatophyte isolates obtained from a large worldwide terbinafine tinea capitis clinical trial , 2008, The British journal of dermatology.

[22]  T. C. White,et al.  Generating and Testing Molecular Hypotheses in the Dermatophytes , 2008, Eukaryotic Cell.

[23]  N. Peres,et al.  Antifungal Resistance Mechanisms in Dermatophytes , 2008, Mycopathologia.

[24]  M. Pfaller,et al.  Review of in vitro activity of sertaconazole nitrate in the treatment of superficial fungal infections. , 2006, Diagnostic microbiology and infectious disease.

[25]  M. Ghannoum,et al.  Voriconazole Susceptibilities of Dermatophyte Isolates Obtained from a Worldwide Tinea Capitis Clinical Trial , 2006, Journal of Clinical Microbiology.

[26]  M. Chadeganipour,et al.  In vitro evaluation of griseofulvin against clinical isolates of dermatophytes from Isfahan , 2004, Mycoses.

[27]  J. Guarro,et al.  In Vitro Activities of the New Antifungal Drug Eberconazole and Three Other Topical Agents against 200 Strains of Dermatophytes , 2003, Journal of Clinical Microbiology.

[28]  J. Guarro,et al.  In vitro Activity of Sertaconazole against Dermatophyte Isolates with Reduced Fluconazole Susceptibility , 2003, Chemotherapy.

[29]  M. Ghannoum,et al.  Clinical Trichophyton rubrum Strain Exhibiting Primary Resistance to Terbinafine , 2003, Antimicrobial Agents and Chemotherapy.

[30]  J. Guarro,et al.  Collaborative Evaluation of Optimal Antifungal Susceptibility Testing Conditions for Dermatophytes , 2002, Journal of Clinical Microbiology.

[31]  J. Guarro,et al.  In Vitro Activities of 10 Antifungal Drugs against 508 Dermatophyte Strains , 2001, Antimicrobial Agents and Chemotherapy.

[32]  S. Rand.  Overview: The treatment of dermatophytosis. , 2000, Journal of the American Academy of Dermatology.

[33]  R. Summerbell,et al.  Tinea Capitis: An Overview with Emphasis on Management , 1999, Pediatric dermatology.

[34]  P. Sohnle,et al.  Advances in dermatophytes and dermatophytosis. , 1992, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.